Susan P. Stimson Sells 2,663 Shares of Intersect ENT Inc (XENT) Stock
Intersect ENT Inc (NASDAQ:XENT) insider Susan P. Stimson sold 2,663 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.00, for a total transaction of $79,890.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Susan P. Stimson also recently made the following trade(s):
- On Wednesday, April 10th, Susan P. Stimson sold 10,000 shares of Intersect ENT stock. The shares were sold at an average price of $29.13, for a total transaction of $291,300.00.
NASDAQ:XENT traded down $0.83 during midday trading on Wednesday, hitting $29.36. The company’s stock had a trading volume of 7,000 shares, compared to its average volume of 270,168. Intersect ENT Inc has a fifty-two week low of $25.09 and a fifty-two week high of $42.95. The company has a market cap of $928.09 million, a PE ratio of -38.63 and a beta of 0.64.
Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Intersect ENT by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 144,802 shares of the medical equipment provider’s stock worth $4,163,000 after purchasing an additional 4,756 shares during the period. BlackRock Inc. grew its stake in shares of Intersect ENT by 12.9% in the third quarter. BlackRock Inc. now owns 2,607,083 shares of the medical equipment provider’s stock valued at $74,954,000 after buying an additional 296,973 shares in the last quarter. Man Group plc grew its stake in shares of Intersect ENT by 32.2% in the third quarter. Man Group plc now owns 10,289 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 2,509 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in shares of Intersect ENT by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 21,677 shares of the medical equipment provider’s stock valued at $623,000 after buying an additional 7,706 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Intersect ENT by 18.9% in the third quarter. AQR Capital Management LLC now owns 51,917 shares of the medical equipment provider’s stock valued at $1,493,000 after buying an additional 8,253 shares in the last quarter. Institutional investors own 97.55% of the company’s stock.
Several equities analysts recently commented on the stock. BidaskClub lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a report on Tuesday, February 26th. Canaccord Genuity increased their price target on shares of Intersect ENT from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, February 26th. ValuEngine upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Saturday, February 23rd. Finally, Zacks Investment Research downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, January 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $37.40.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2019/04/24/susan-p-stimson-sells-2663-shares-of-intersect-ent-inc-xent-stock.html.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Further Reading: Day Trading
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.